Claus Marcher
Overview
Explore the profile of Claus Marcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norskov K, Fridthjof K, Kampmann P, Dunweber A, Andersen C, Renaberg T, et al.
Leuk Res
. 2021 Nov;
112:106756.
PMID: 34839055
Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with...
2.
Larsen T, Iversen K, Hansen E, Mathiasen A, Marcher C, Frederiksen M, et al.
Leuk Res
. 2013 Jul;
37(9):1041-5.
PMID: 23827351
Within recent years data has accumulated demonstrating the efficacy of recombinant interferon alpha2 (rIFN-alpha2) in the treatment of chronic myeloproliferative neoplasms (MPNs). We report on clinical and molecular data in...
3.
Cheng G, Saleh M, Marcher C, Vasey S, Mayer B, Aivado M, et al.
Lancet
. 2010 Aug;
377(9763):393-402.
PMID: 20739054
Background: Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We aimed to compare the response to once daily eltrombopag versus placebo in patients with chronic immune...
4.
Larsen T, Moller M, de Stricker K, Norgaard P, Samuelsson J, Marcher C, et al.
Hematology
. 2009 Nov;
14(6):331-4.
PMID: 19941739
Polycythemia vera (PV) is characterized by the presence of the JAK2V617F mutation in virtually all patients. Several studies have shown that the JAK2V617F mutational load decreases during treatment with alpha-interferon...